Table.

Summary of Guidance for Pre-exposure Prophylaxis (PrEP) Use

Men Who Have Sex With Men	Heterosexual Women and Men	People Who Inject Drugs
Detecting Substantial Risk of Acquiring HIV Infection
Sexual partner with HIV Recent bacterial STI High number of sex partners History of inconsistent  or no condom use Commercial sex work	Sexual partner with HIV Recent bacterial STI High number of sex partners History of inconsistent  or no condom use Commercial sex work Lives in high-prevalence area  or network	HIV-positive injecting partner Sharing injection equipment Recent drug treatment (but currently  injecting)
Clinically Eligible
Documented negative HIV test before prescribing PrEP No signs/symptoms of acute HIV infection Normal renal function (serum creatinine), no contraindicated medications
Prescription
Daily, continuing, oral doses of TDF/FTC (Truvada), ≤90 day supply Follow-up visits at least every 3 months to provide: HIV test, medication adherence counseling, behavioral risk reduction support, side effect assessment, STI symptom assessment At 3 months and every 6 months after, assess renal function Every 6 months test for bacterial STIs Document hepatitis B virus infection and vaccinate non-immune individuals
Other Services
Do oral/rectal STI testing	Assess pregnancy intent Pregnancy test every 3months	Access to clean needles/syringes and drug treatment services

Abbreviation = sexually transmitted infections, STI.

Source: US Public Health Service.¹